Literature DB >> 8528431

Time preference, duration and health state valuations.

P Dolan1, C Gudex.   

Abstract

There is increasing interest in health status measurement and the relative weights that people attach to different states of health and illness. One important issue which has been raised is the effect that the time spent in a health state may have on the way that state is perceived. Previous studies have suggested that the worse a state is, the more intolerable it becomes as it lasts longer. However, for most of these studies, it is impossible to determine how much of what was observed is attributable to the time spent in the state and how much is attributable to when it was occurring. This paper reports on a pilot study designed to test the feasibility of using the Time Trade-Off (TTO) method to isolate the effect of pure time preference from the effect of duration per se. Interviews were conducted with 39 members of the general population who were asked to rate 5 health states for durations of one month, one year and ten years. In aggregate, rates of time preference were very close to zero which suggests that the implicit assumption of the TTO method that there is no discounting may be a valid one. However, that more respondents had negative (rather than positive) rates, casts some doubt on the axions of discounted utility theory. In addition, implied valuations for states lasting for short periods were often counter-intuitive which questions the feasibility of using the TTO method to measure preferences for temporary health states.

Entities:  

Mesh:

Year:  1995        PMID: 8528431     DOI: 10.1002/hec.4730040405

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  19 in total

Review 1.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

2.  Measurement of short term health effects in economic evaluations.

Authors:  A M Holmes
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

3.  An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.

Authors:  S Hummel; J Piercy; R Wright; A Davie; A Bagust; J McMurray
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

4.  Health state valuations from the general public using the visual analogue scale.

Authors:  C Gudex; P Dolan; P Kind; A Williams
Journal:  Qual Life Res       Date:  1996-12       Impact factor: 4.147

5.  Health Valuation: Demonstrating the Value of Health and Lifespan.

Authors:  Elly A Stolk; Benjamin M Craig; Brendan Mulhern; Derek S Brown
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

6.  Time to tweak the TTO: results from a comparison of alternative specifications of the TTO.

Authors:  Matthijs M Versteegh; Arthur E Attema; Mark Oppe; Nancy J Devlin; Elly A Stolk
Journal:  Eur J Health Econ       Date:  2013-07

7.  Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.

Authors:  Arthur S Zbrozek; Gary Hudes; Donna Levy; Andrew Strahs; Anna Berkenblit; Robert DeMarinis; Shreekant Parasuraman
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.

Authors:  David F Moore; Markus Ries; Evelyn L Forget; Raphael Schiffmann
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status.

Authors:  Helen M McTaggart-Cowan; Carlo A Marra; Yaling Yang; John E Brazier; Jacek A Kopec; J Mark FitzGerald; Aslam H Anis; Larry D Lynd
Journal:  Qual Life Res       Date:  2008-02-15       Impact factor: 4.147

10.  Validation of the functional assessment of cancer therapy-gastric module for the Chinese population.

Authors:  Hui Jun Zhou; Jimmy B Y So; Wei Peng Yong; Nan Luo; Feng Zhu; Nasheen Naidoo; Shu Chuen Li; Khay Guan Yeoh
Journal:  Health Qual Life Outcomes       Date:  2012-11-30       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.